Pre-made Nesvacumab benchmark antibody ( Whole mAb, anti-ANGPT2 therapeutic antibody, Anti-AGPT2/ANG2/LMPHM10 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Nesvacumab biosimilar, Whole mAb, Anti-ANGPT2 Antibody: Anti-AGPT2/ANG2/LMPHM10 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2. As of May 2017, it is in Phase II clinical trials for the treatment of diabetic macular edema.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-373-1mg	1mg	3090
GMP-Bios-ab-373-10mg	10mg	Inquiry
GMP-Bios-ab-373-100mg	100mg	Inquiry
GMP-Bios-ab-373-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Nesvacumab biosimilar, Whole mAb, Anti-ANGPT2 Antibody: Anti-AGPT2/ANG2/LMPHM10 therapeutic antibody
INN Name	Nesvacumab
Target	ANGPT2
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2012
Year Recommended	2013
Companies	Regeneron Pharmaceuticals;Sanofi
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Solid tumours
Development Tech	na